Sodium glucose cotransporter 2 inhibitors and glucagon-like peptidase-1 receptor agonist use for T2DM can decrease transaminase activity in patients with NAFLD [27,28,29,30]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.